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SUMMARY 
 
Various signal transduction pathways, and various proteins of the blood-brain barrier 
(BBB) seem to be involved in chemoresistance of pediatric glioblastoma multiforme 
(GBM). MicroRNA-21 (miR-21) is an important oncogenic microRNA (miRNA) which 
modulates drug resistance of tumor cells.  
Breast cancer resistance protein (BCRP) and P-glycoprotein (P-gp) are ATP-binding 
cassette (ABC) transporters that also remove drugs through BBB, limiting brain 
penetration and accumulation. These proteins are also expressed by cancer cells, but 
their role in chemoresistance is unclear.  
In GBM and in other brain tumors, miR-21 seems regulate the expression levels of 
BCRP and P-gp with an indirect regulation mechanism.  
It has already been shown that doxorubicin (DOX) is an effective anti-glioma agent 
with antitumor activity also against GBM stem cells. However clinical trials 
disappointed these data. Preclinical studies suggest that chemoresistance is a multi-
levels, dynamic reality, that can be modulated. In particular, in animal models, 
Morphine (Morph) temporarily alters the permeability of BBB for large molecules, such 
as DOX. However, its role is unknown in cellular resistance. Moreover, prolonged 
exposure to DOX showed a significant induction of apoptosis in GBM stem cells while 
the commonly used etoposide and temozolomide were not quite effective. 
We analyzed the expression of 5 miRNAs, previously found to be dysregulated in high 
grade gliomas (HGG), in 9 pediatric GBM samples. Furthermore, we selected a DOX 
resistant GBM cell line with similar miRNA expression profile, in order to study 
mechanisms of chemoresistance (miRNAs and ABC trasporters). 
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Analysis on pediatric GBM samples showed an overexpression of miR-21 and a 
reduced or lack of expression of miR-7, miR-124, miR-128 and miR-137. 
Analysis of sensitivity to DOX in 3 GBM cell lines (A172, U87MG and T98G) showed 
a cytotoxic effect after 48h of treatment in A172 and U87MG, but not in T98G cells. 
TUNEL assay verified also that DOX induced apoptosis in A172 and U87MG but not in 
T98G. About miRNA expression profile in this cell line, miR-21 in T98G cells was 
over-expressed likely pediatric GBM samples. 
We evaluated both the role of Morph and prolonged exposure to DOX, on 
chemoresistance of T98G. In our experience, treatment with Morph plus DOX did not 
interfere with the cytotoxic effect of chemotherapy that was observed only after 
prolonged exposure to anthracycline (96h). 
Moreover we evaluated the role of miR-21 and ABC transporters in DOX 
chemoresistance of T98G cells.  
To validate the possible association of miR-21 with drug resistance of T98G cells, we 
transfected anti-miR-21 inhibitor into the cells. The expression level of miR-21 was 
significantly lower in T98G transfected cells (than in the parental control ones). 
Transfected cells showed a high apoptotic rate compared to control after DOX treatment 
by TUNEL assay, suggesting a key role of miR-21 in DOX chemoresistance.  
Finally, we evaluated the cellular expression (basal and after treatment) of P-gp and 
BCRP in T98G cells. T98G cells constitutively express BCRP, but not P-gp. After 
treatment with DOX or DOX plus Morph we have seen that both DOX and Morph 
down-regulate BCRP expression. 
In conclusion, we have demonstrated that miR-21 was over-expressed in T98G GBM 
cells and in our pediatric GBM samples. miR-21 could play an important role in DOX 
	  	  viii	  
chemoresistance of T98G cells. However, DOX chemoresistance seems to be 
independent from BCRP expression and Morph co-treatment. Only prolonged exposure 
(96h) to DOX makes T98G cells sensible to DOX. 
 
 
KEY WORDS 
 
pediatric glioblastoma multiforme, miR-21, BCRP, P-gp, doxorubicin, chemoresistance, 
blood-brain barrier 
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CHAPTER 1. INTRODUCTION 
 
 
1.1. Glioblastoma in pediatric and adult patients 
 
Glioblastoma (GBM; synonymous with the formerly used term ‘glioblastoma 
multiforme’) is the most frequent and most aggressive malignant primary brain tumour 
in adult population [1,2], and is classified as grade IV in the World Health Organization 
classification of tumours of the central nervous system (WHO classification of tumours 
of the CNS) [1]. GBM can develop from lower-grade diffuse astrocytoma (WHO grade 
II) and anaplastic astrocytoma (WHO grade III), and is then termed ‘secondary’ GBM 
(approximately 5% of cases). ‘Primary’ (de novo) GBMs are more common 
(approximately 95% of cases), and they typically manifest rapidly after a short clinical 
history and without recognizable signs of a preceding precursor lesion [3]. Diagnostic 
criteria for GBM, including high mitotic activity, microvascular proliferation and/or 
necrotic areas, are fulfilled by both primary and secondary GBM, which makes them 
indistinguishable by histology alone [1]. 
Overall, primary GBM accounts for 16% of primary brain tumours [2]. The incidence 
increases with age: it affects an average of 7.2 per 100,000 adults (≥19 years of age) 
every year, with a peak age at diagnosis between 75 and 84 years (annual incidence rate 
14.6 per 100,000 individuals) [2]. Owing to the lower incidence in children, studies on 
paediatric high-grade gliomas (HGGs) have traditionally combined GBM, anaplastic 
astrocytomas and diffuse intrinsic pontine gliomas (DIPGs). Although most DIPGs 
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histologically present as high-grade tumors and share a universally fatal outcome, they 
comprise tumors with varying histological grades and divergent differentiation [4-7].  
Data on childhood malignancies from the EU show that HGGs are rare, with 
glioblastomas and anaplastic astrocytomas accounting for 2.8% and 1.9%, respectively 
of central nervous system (CNS) tumors, and 6.8% of CNS tumors located in the pons 
(including DIPG) [8]. 
Together, up to 0.8 per 100,000 children (<19 years of age) are estimated to develop 
HGGs each year [2]. 
The current treatment strategy for GBM patients consists of surgery, radiotherapy and 
chemotherapy. Complete surgical resection of these infiltrative tumors is virtually 
impossible, yet gross total resection is still a positive prognostic marker. Surgery is 
typically not attempted for patients with DIPG because of the location of these gliomas. 
Concurrent adjuvant radiotherapy in combination with temozolomide represents the 
standard of care for adults patients with newly diagnosed GBM, but still less than 5% of 
patients survive for longer than 5 years after diagnosis [2,9-11]. However, prognosis is 
better for children than for adults [12]. Children have a 5-year survival rates ranging 
from 5% to 10% for supratentorial GBM. Surgery and radiation are the usual modes of 
therapy for pediatric HGG. No effective chemotherapy regimens have been identified 
for any pediatric HGG. 
In both adult and pediatric patients, no chemotherapeutic drugs have proven to be 
effective in the treatment of DIPG. Radiation therapy alone represents the current 
standard regimen [13,14]. In this case, prognosis is even worse, with less than 10% of 
patients with DIPG surviving for more than 2 years after diagnosis [2,15].  
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1.2. Blood-brain barrier and chemoresistance 
 
1.2.1. Physiology of the blood-brain barrier 
The major problem in drug delivery to brain is the presence of the blood-brain barrier 
(BBB). Drugs that are effective against diseases in the CNS and reach the brain via the 
blood compartment must pass the BBB.  
The BBB is one of a number of blood-CNS interfaces, which also include the blood–
cerebrospinal fluid (CSF) barrier, the blood–retinal barrier, the blood–nerve barrier and 
the blood–labyrinth barrier; all of which are important for the physiological functions of 
the CNS. Among these interfaces, the BBB occupies by far the largest surface area. 
BBB is dynamic, with a wide permeability range that is controlled by intra- and inter-
cellular signaling events among endothelial cells, astrocytes and neurons in the complex 
(and other cells that are in contact with the BBB), as well as by paracellular changes at 
the BBB. 
BBB is an integral part of the neurovascular unit (NVU), which also plays a part in the 
control of cerebral blood flow and neuronal development [16]. A classical view of the 
NVU incorporates neurons, glial cells such as astrocytes and microglial cells closely 
juxtaposed with vascular endothelial cells, pericytes and smooth muscle cells. Blood 
cells, particularly polymorphonuclear (PMN) cells, lymphocytes and monocytes, also 
interact with the BBB endothelium and are therefore an integral part of this unit. The 
interactions between these cellular components and inter- and intra-cellular signalling 
regulate NVU function to maintain homeostasis, or to respond to inflammation and 
disease [17].  
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The BBB to macromolecules and most polar solutes is created by tight junctions (TJs) 
between the cerebral endothelial cells, the choroid plexus epithelial cells and the cells of 
the arachnoid epithelium. Extremely tight ‘tight junctions’ (zonulae occludentes) are a 
key feature of the BBB and significantly reduce permeation of polar solutes through 
paracellular diffusional pathways between the endothelial cells from the blood plasma 
to the brain extracellular fluid. The tight junctions are responsible for the severe 
restriction of the paracellular diffusional pathway between the endothelial cells to ions 
and other polar solutes, and effectively block penetration of macromolecules by this 
route [18,19]. 
 
Figure 1. Routes of transport across the blood-brain barrier. 
 
 
 
There are several routes of transport across the BBB (Figure 1); some molecules may 
passively diffuse across the BBB from blood to brain or from brain to blood, others may 
pass the BBB through a wide range of different carriers or may be transported by 
specific and non-specific transcytotic mechanisms. 
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Passive diffusion: passive diffusion is facilitated from high lipid solubility [20], but 
limited by other physicochemical factors such as a high polar surface area, the tendency 
to form more than 6 hydrogen bonds, the presence of rotatable bonds or a high 
molecular weight [20,21]. This route of permeation is also limited by the action of 
active efflux carriers, belonging to the family of ATP-binding cassette transporters 
(ABC transporters), that pump the passively penetrating solutes out of the endothelial 
cell [22].  Due to the action of these transporters, increasing the lipid solubility of a 
molecule could lead to a minor passive diffusion, in the case that the lipid components 
increase the affinity of the molecule to the ABC transporter itself [22-25]. Moreover, 
the movement of the blood gases oxygen and carbon dioxide across the BBB is 
diffusive and the dissolved gases move down their concentration gradients. 
ATP-binding cassette transporters: the ABC transporters function as ATP-dependent 
active pumps. They remove from the CNS potentially neurotoxic endogenous or 
xenobiotic molecules [26]. Intriguingly, many drugs are substrates for these ABC efflux 
transporters and their brain penetration is significantly reduced by their action [22]. The 
most important ABC transporters are P-glycoprotein (Pgp, Multidrug Resistance 
Protein, ABC-B1), the Multidrug Resistance-associated Proteins (MRPs, ABC-C1, 2, 4, 
5 and possibly 3 and 6), and Breast Cancer Resistance Protein (BRCP, ABC-G2) 
[22,27,28]. Pgp and BCRP are expressed in the luminal membrane of the BBB, to 
transport substrate from endothelium to blood. Instead some of the MRP isoforms are 
expressed in either the luminal or the abluminal membrane, or sometimes both [29]. 
Indeed the transport activity of both pericytes [30] and perivascular astrocyte endfeet  
may contribute to barrier function as a second defense if the primary barrier (brain 
endothelium) is breached or dysfunctional [31]. Transporters are also involved in the 
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regulation of the import/export of xenobiotics, including CNS drugs, and can affect  
their  pharmacokinetics and pharmacodynamics. Intracellular signaling pathways 
represent a possible target to regulate the activity and the expression of efflux 
transporters. 
Solute carriers in the BBB: molecules that cannot diffuse through cell membranes need 
a carrier, thus all cells of BBB express a large number of solute carriers (SLCs) in the 
cell membrane [32]. Some of these transport proteins are polarized and are inserted into 
either the luminal or abluminal membrane only, others are inserted into both membranes 
of the endothelial cells. Therefore, the orientation of these transporters may result in 
preferential transport into or across the endothelial cell (from blood to brain or brain to 
blood) [29,33,34]. SLCs influx through BBB may be passive, or active and can 
transport many essential polar molecules such as glucose, amino acids and nucleosides 
into the CNS. The solute carriers may be bi-directional or unidirectional either into or 
out of the cell.   
Transport of macromolecules: the main route for the transport of macromolecules 
through the BBB is endocytosis. These mechanisms involve either receptor-mediated 
transcytosis (RMT) or adsorptive-mediated transcytosis (AMT). Both RMT and AMT 
are vesicular-based systems to carry macromolecules across the cerebral endothelium. 
RMT is induced by the binding of the ligand with the receptor and can transport such as 
peptides and proteins. AMT is induced in a non-specific manner by positively charged 
macromolecules [35]. 
Cell movement across BBB: leukocytes may be enrolled by the CNS in pathological 
conditions, and play complementary functions with resident microglia [36]. Leukocytes 
cross the BBB either by a process of diapedesis through the endothelial cells 
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(penetrating close to the tight-junctions), or via modified tight-junctions. The junction-
associated molecules (JAMs) and the cell surface protein CD99 may interact with the 
leukocytes to initiate diapedesis [37].  The BBB tight-junctions open in inflammation 
mechanism; this modulation can result from both cell cytokines associated with the 
brain endothelium and it can be induced pharmacologically; molecular re-arrangement 
of the proteins of the tight-junctions results in complete or partial opening of the 
paracellular aqueous diffusion pathway [38-40]. 
 
1.2.2. Blood-brain barrier in pathology 
There is a growing list of CNS pathologies involving an element of BBB dysfunction, 
including multiple sclerosis, hypoxia and ischemia, edema, Parkinson's disease and 
Alzheimer's disease, epilepsy, tumors, glaucoma and lysosomal storage diseases. In 
cancers, the barrier dysfunction can range from mild and transient tight junction 
opening to chronic barrier breakdown, and changes in transport systems and enzymes 
can also occur [41]. 
 
1.2.3. Blood-brain barrier regulation 
It is increasingly recognised that the BBB is a dynamic system, capable of responding to 
local changes and requirements, and able to be regulated via a number of mechanisms 
and cell types, in both physiology and pathological conditions. Such regulation includes 
changes in tight junction function [42], and in expression and activity of many 
transporters and enzymes [43,44]. Regulation is an efficient means of matching the 
activities of the BBB to the requirements of the brain, whether for protection from 
circulating agents, adjustment of nutrient supply, or modification to facilitate local 
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repair. This emphasizes again the key role played by the brain endothelium and its 
associated cells in the daily functions of the brain. As more is learned about BBB 
regulation, opportunities will emerge for targeting the brain endothelium to maintain 
health and to aid recovery from injury or infection, so that the BBB becomes integral to 
developing strategies for drug therapy to the brain [43]. 
 
 
1.3. In vitro and in vivo studies of anthracyclines on central nervous system tumors 
 
Anthracyclines are a class of antitumor antibiotics, produced by the Streptomyces 
peucetius varieta caesius, actually used in the treatment of many tumors including 
leukemias, lymphomas, breast, uterine, ovarian, bladder and lung cancer [45]. 
Doxorubicin (DOX), a nonselective class I anthracycline, has shown great treatment 
potential and is being regarded as one of the most used of the Food and Drug 
Administration-approved chemotherapeutic drugs [46]. This drug principally acts by 
binding to DNA associated enzymes, such as topoisomerase I and II, thus interfering 
with the normal DNA replication and inducing, as a result, programmed cell death. 
Other DOX mechanisms of actions include free radical generation which causes further 
DNA damage, inhibition of macromolecules production, DNA unwinding/separation 
and increase in alkylation.  
DOX, due to its cytotoxic and pro-apoptotic effect, has been also tested in tumors 
involving the CNS, and numerous in vitro studies have been performed in order to 
evaluate the its efficacy in primary cell cultures and cell lines of brain tumor.   
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Cancer stem cells have been reported to be an important tumorigenic population in 
GBM; their proliferative potential being required for tumor development and 
maintenance [47]. 
In “in vitro” studies, undifferentiated GBM primary cells were exposed to commonly 
used antineoplastic drugs daunorubicin, etoposide, campothectin, temozolomide and 
DOX, in order to evaluate the effect of this chemotherapeutic agents on cell survival 
and expansion. After 48 hours of treatment, a marked resistance of GBM stem cells was 
observed to all the used compounds whereas controls (hematopoietic cells). Only after 
prolonged exposure (96 hours) to anthracyclines, in particular DOX, the GBM stem 
cells displayed an induction of apoptosis, while the commonly used etoposide and 
temozolomide were not quite effective [48]. 
Moreover, others in vitro experiments demostrated that U87MG glioblastoma-
astrocytoma epithelial-like cell line, and A172 GBM cell line are very sensitive to DOX 
exposure [49].  
Despite all these “in vitro” results suggest that DOX could be hypothetically used to 
treat HGG, “in vivo” studies and preliminary data of clinical trials seem to demonstrate 
DOX has very limited efficacy on CNS tumors. These disappointing outcomes can be 
attributable primarily to the poor BBB penetration of the DOX [50], which must be 
administered systemically, at cardiotoxic and nephrotoxic doses, to exert any 
therapeutic benefit [51]. 
One of the underlying mechanisms of this BBB-mediated drug resistance is the over-
expression of distinct set of efflux proteins, such as ABC transporters. In humans, the 
major ABC efflux pumps involved in the MDR phenotype, are P-gp, BCRP and MRPs 
that restricting the brain penetration of many antineoplastic agents, including DOX [52]. 
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Therefore, several invasive strategies have been tested for improving anthracycline 
delivery to brain parenchyma through circumvention of the BBB.  
Recently, intracerebral drug delivery of DOX via a polymer matrix in brain tumors has 
been successfully performed [53]. A clinical study has shown encouraging results with 
intralesional DOX infusion via an Ommaya reservoir without significant systemic side 
effects for therapy of HGGs [54]. 
Moreover, it has been proposed to use some adjuvant molecules for modulating and 
opening the BBB during administration of chemotherapy agents that normally are not 
able to effectively cross it [55-58]. 
Sharma and Ali [56] demonstrated in a rodent model that morphine (Morph), the most 
frequently used analgesic in oncological cancer patients, temporarily alters the 
permeability of BBB for large molecules. A modulation of the BBB by Morph could 
therefore act as permeability enhancer also for chemotherapy agents, as anthracyclines, 
normally unable to effectively enter the brain. 
Moreover, Morph pre-treatment facilitates DOX delivery beyond the BBB to the brain 
in the absence of signs of increased acute systemic toxicity in a rat model [59]. 
Thus, it is conceivable that Morph inhibiting ABC transporters localized on BBB, 
neurons and glial cells could increase the access of DOX to the brain competing with 
the same efflux transporter that very efficiently removes these drugs from the CNS [60]. 
A prerequisite for the efficacy of antineoplastic agent is that it reaches the tumor lesion 
in therapeutic concentrations. In brain tumors, the mechanism is complicated by the 
BBB, which is a major physical and physiological hurdle for the delivery of 
chemotherapy bioactivities in the brain. 
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1.4. MicroRNAs: essentials of biology and role in anthracyclines chemioresistance 
 
1.4.1. Essentials of biology 
MicroRNAs (miRNAs) are short non-coding RNAs of 20-24 nucleotides that play 
important roles in virtually all biological pathways in mammals and other multicellular 
organisms. Accordingly, miRNAs influence numerous cancer-relevant processes such 
as proliferation, cell cycle control, apoptosis, differentiation, migration and metabolism. 
For most miRNAs, pre-miRNA transcripts are generated by RNA polymerase II, either 
as separate transcriptional units or embedded within the introns of protein coding genes. 
Pre-miRNA hairpin is subsequently exported to the cytoplasm by exportin 5. In the 
cytoplasm, a protein complex produce the single-stranded mature miRNA, which 
subsequently incorporates into the RNA induced silencing complex (RISC). The mature 
miRNA then induces post-transcriptional gene silencing by tethering RISC to partly 
complementary sequence motifs in target mRNAs predominantly found within the 3’ 
untranslated regions (UTRs) [61-63].  
As a single miRNA may target up to several hundred mRNAs, aberrant miRNA 
expression may affect a multitude of transcripts and profoundly influence cancer-related 
signaling pathways. It was also reported that miRNAs could bind to the coding region, 
or the 5’ UTRs [64]. 
 
1.4.2. Role in anthracyclines chemioresistance 
The miRNA-mediated drug resistance is one of the underlying mechanisms of the 
complex biological phenomenon known as MDR. A single miRNA may target up to 
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several hundred mRNAs, thus playing an important role in many biological and 
physiological processes, including drug resistance.   
The resistance can be innate or acquired. It may exist in tumor cells since the beginning 
of therapy or tumor cells may acquire resistance during treatment, becoming resistant to 
a range of chemical compounds.  
A mechanism of resistance is due to an over-expression of ABC proteins on cell 
membrane, as P-gp/ABC-B1/MDR1, MRP/ABC-C family and BCRP/ABC-G2, all of 
which drive efflux away from the CNS by an ATP-dependent process.  
Recent studies suggested that miRNAs may regulate the resistance genes such as 
BCRP/ABC-G2 [65] and P-gp/ABC-B1/MDR1 [66] and that the modulation of their 
expression or function may alter the chemosensitivity of cancer cells to chemotherapy. 
[67,68].  
The molecular mechanisms underlying the post transcriptionally miRNAs-mediated 
regulation include direct binding of miRNA to the 3’-UTR mRNA of ABC-G2 or 
MDR1 (direct regulation) or binding others mRNAs that affect the expression levels of 
others proteins (indirect regulation). In addition, miRNAs-mediated regulation may also 
occur at the transcriptional level, by targeting the ABC-G2 or MDR1 promoter region 
[69].  
A great number of studies have been performed to demonstrate linking about miRNAs 
expression patterns to specific alterations in ABC proteins. MiR-200c has been reported 
to modulate the resistance to epirubicin in breast cancer cells by targeting P-gp [70]; 
miR-328, miR-212, miR-519c and miR-520h negatively regulate the expression of 
BCRP in human cancer cells [71]; miR-27a, miR-145, miR-298, miR-331-5p, miR-451, 
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miR-1253 can directly bind the 3′-UTR of the MDR1 mRNA and reduce P-gp 
expression in leukemia and breast cancer [72-75].  
Conversely, the up-regulation of MDR1 transcription involves miR-19a/b, that is 
considered the major determinant in DOX efflux of gastric cancer cells [76], miR-296, 
miR-138, miR-27a and miR451, although the exact mechanism of their indirect 
modulation remains unclear [66,77-79].  
Recently, a study performed by Gisel and co-workers, verified the down or up-
regulation of certain miRNAs in wild type cell line (MDCK cells) and in the counterpart 
of cells over-expressing P-gp (MDCK-MDR1 cells), both treated with a P-gp substrate 
and a specific P-gp inhibitor. The authors identified a set of four human miRNAs (miR-
424-3p, miR-130a-3p, miR-218-5p, miR181a-5p), specifically down or up-modulated 
by the P-gp substrate, in MDCK and MDCK-MDR1 cells, demonstrating the link 
between miRNAs expression and Pgp-mediated MDR [80].  
In brain tumors, the low efficacy of chemotherapy is primarily due to the BBB; on the 
other hand, cancer cells often exhibit an innate resistance and the over-expression of P-
gp and BCRP efflux pumps is the major determinant of chemoresistance at cellular 
level. Cells derived from HGGs can constitutively over-express ABC proteins to 
increase the drug efflux. Increases in drug efflux are responsible for enhanced drug 
resistance [81].  
Based on “in vitro” experiments, miR-328 is able to target the 3’-UTR of BCRP/ABC-
G2, thereby negatively regulating BCRP expression in human cancer cells [65], 
including GBM cancer stem cells [82]. A decreased BRCP expression results in 
increased sensitivity to different drugs.  
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In contrast, the over-expression of miR-21, an oncogenic miRNA up-regulated in many 
tumors including GBMs, leads to increased BCRP-mediated resistance through an 
indirect regulation.  
Subsequently, Pradhan and co-workers have demonstrated that the activation of NF-κB 
signaling, caused by miR-21-mediated suppression of the negative regulator leucine rich 
repeat (in FLII) interacting protein 1 (LRRFIP1), induces the up-regulation of ABCG2 
and thus increases tumor drug resistance [83].  
In addition to miR-21, it has been demonstrated that miR-27a and miR-451 are widely 
deregulated in HGGs [84,85].  Since they seem to act as promoters of P-gp expression 
in cancer cells [65], literature data highlight their major role in supporting tumor 
chemoresistance [86]. 
In conclusion, as exemplified, many miRNAs suppress the transcription of the MDR1 
or ABC-G2 gene, whereas several miRNAs enhance it.  
Each of them may be used for diagnostic and prognostic purposes, and they represent 
today hopeful therapeutic targets for improvement of effectiveness to chemotherapy in 
cancer cells. 
miR-21 promotes cell invasion, by regulating multiple genes, including PTEN, RECK 
and MARCKS, in several types of cancers, such as glioma, ovarian epithelial carcinoma 
and prostate cancer [87-89]. miR-21 overexpression in human breast cancer is 
associated with advanced clinical stage, lymph node metastasis and poor prognosis [90], 
and its dysregulation plays a critical role in DOX resistance of breast cancer via 
targeting PTEN [91]. 
As previously described, miR-21 is significantly altered in human adult GBMs. 
Moreover, it has been demonstrated that we found that higher expression of miR-21 is 
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associated with early disease progression despite anticancer multidisciplinary treatments 
(surgery, radiotherapy, and chemotherapy) [92]. 
 
 
1.5. Role of cancer cell expression of BCRP and P-gp 
 
BCRP is highly expressed at the plasma membrane of tumor stem cells [93,94], where it 
could be involved in stem cell differentiation, protection against xenobiotics, and cancer 
cell survival under hypoxic conditions [95]. Little is known about BCRP expression in 
brain cancer. In primary CNS lymphoma, BCRP protein expression and transport 
activity have been shown to be down-regulated [96]. In contrast, in neuroepithelial 
tumors such as ependymomas and in glioma tumor stem-like cells BCRP protein and 
activity are highly up-regulated, causing multidrug resistance [97-99]. 
In addition, P-gp was found in primary brain tumors and is now recognized to be a 
critical transporter that conveys resistance to a large number of anti-cancer drugs, for 
example taxanes, vinca-alkaloids, etoposide and analogues, anthracyclines, lanafarnib, 
imatinib, and topotecan [100,101]. Thus, P-gp has been a focus of BBB, brain tumor, 
and drug delivery research for almost two decades. 
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CHAPTER 2. ROLE OF miR-21 AND BCRP IN DOXORUBICIN 
CHEMORESISTANCE OF PEDIATRIC GLIOBLASTOMAS 
 
 
2.1. Rationale and objectives of the study 
 
2.1.1. Rationale 
Alterations in miRNA expression levels are associated with a number of neural diseases 
and brain tumors. Recently, specific miRNA expression profiles have been identified in 
GBMs, but there are only limited data on the role of miRNA in pediatric GBM.  
Therefore, investigation of miRNA expression profiles can be useful to determine 
whether they are involved in determining chemoresistance to specific anticancer 
treatment, like DOX. 
Is also known that chemoresistance is a multi-levels, dynamic reality, that can be 
modulated. Adjuvant drugs like Morph or prolonged exposure to DOX can modulate the 
resistance mainly by alteration of the BBB permeability. However, the role of Morph in 
normal or prolonged exposure on cellular chemoresistance is unknown.  
P-gp and BCRP are ABC efflux transporters localized on BBB, blood-tumor barrier, on 
cancer cells and cancer stem cells. P-gp and BCRP-mediated drug resistance in brain 
tumors is principally due to transporter up-regulation at the BBB. The role of these 
transporters on cellular mechanisms of chemoresistance is still unclear.  
We analyzed these complex mechanisms of drug resistance, in a cell model with similar 
miRNA expression profile to those of pediatric GBM samples. 
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2.1.2. Objectives of the study 
This study was conducted with a series of steps for the evaluation of multiples theories 
regarding mechanisms of DOX chemoresistance in pediatric GBM and in GBM cell 
lines. 
The steps of this study are: 
• Evaluation of miRNA expression profiles (miR-21, miR-7, miR-124, miR-128 
and miR-137) in samples of pediatric GBM: this analysis is performed to select 
profiles that may have a role in these tumors, and that can be studied in further 
analysis on cell lines. 
• Evaluation of miRNA expression profiles (miR-21, miR-7, miR-124, miR-128 
and miR-137) in GBM cell lines (U87MG, A172, and T98G): this analysis is 
performed to select cell lines that have miRNA expression profiles similar to 
pediatric GBM. 
• GBM cell lines and DOX resistance: to select GBM cell lines that are resistance 
to DOX, from those with miRNA expression profiles similar to pediatric GBM. 
• Cytotoxic effect of DOX and DOX plus Morph in DOX resistance cell lines, 
after normal and prolonged exposure: to evaluate the effect of Morph and the 
effect of prolonged exposure on DOX sensitivity in resistant cell lines. 
• Effects of concomitant DOX treatment and selected miRNA inhibitor: to 
evaluate the role of selected miRNA expression in DOX chemoresistance. 
• P-gp and BCRP expression in resistant cell lines before and after DOX plus 
Morph treatment: to evaluate expression changes of P-gp and BCRP with 
concomitant DOX and Morph treatment. 
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2.2. Materials and methods 
 
2.2.1. Patients 
Tumor samples of pediatric patients with GBM (WHO-grade IV) were collected. 
Patients with GBM seen between 2008 and 2013 at Meyer Children’s University 
Hospital in Florence were eligible for this study. Histological diagnosis and tumor 
grading had to be carried out based on 2007-World Health Organization (2007-WHO) 
criteria [27]. Diagnosis had to be confirmed by the review of the CNS national panel of 
pathologists. 
The study was approved by the institutional Ethical Committee.  
Informed consent was obtained in all cases. 
 
2.2.2. Cell lines 
Three human GBM cell lines, A172, U87MG and T98G, were employed in this study 
(American Type Culture Collection; ATCC). U87MG and T98G were grown in Eagle’s 
Minimum Essential Medium, while A172 was grown in Dulbecco’s Modified Eagle 
Medium. Each medium was supplemented with 10% fetal bovine serum and 1% 
penicillin-streptomycin. All cell lines were maintained in a humidified atmosphere of 
5% CO2-95% air at 37°C.  
Cells from exponentially growing cultures were used for all experiments. 
 
2.2.3. Drugs 
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DOX (Adriblastina 50 mg vials) was obtained from commercial sources (Pfizer) and 
tested at various plasma peak concentrations [28] for miRNA expression studies. Doses 
of 0.1 and 0.5 µg/ml were used for MTT and TUNEL assay.  
The drug was prepared immediately prior to use. 
Morph (Morfina Cloridrato 10 mg vials) was also obteined from commercial sources 
(Molteni). Morph was used in co-treatment with DOX, for MTT assay and for western 
blot analysis.  Cells were treated with a single dose of Morph 20 uM. Two hours after, 
the excess of Morph was removed, and the cells were treated with DOX. 
The drug was prepared immediately prior to use. 
 
2.2.4. In vitro drug assay 
U87MG, A172 and T98G cell lines were seeded in a volume of 3 ml at 1 × 105 
cells/well in 6-well plates, allowed to adhere for 24 hours and subsequently exposed to 
the drugs for 12, 24 and 48 hours. 
The following DOX concentrations were used: 8.34 µg/ml for T98G and U87MG, and 
0.834 µg/ml for A172.  
Untreated cells were used as a negative control.  
All experiments were conducted in triplicate. 
 
2.2.5. miRNAs expression study 
miRNAs were extracted with RecoverAll® Total Nucleic Acid Isolation (Ambion) from 
paraffin-embedded tissues (3-5 slices of tissue with a thick ≥ 10 µm) and with 
mirVana® miRNA Isolation Kit (Ambion) from pellets of cell lines. 
miR-21, miR-7, miR-124, miR-137 and miR-128 expression levels were determined 
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using commercial assays (Assay on demand, Applied Biosystems) on a 7700 ABI 
PRISM Sequence Detector (Applied Biosystems). 
Real-time polymerase chain reaction (RT-PCR) was performed on cDNAs synthesized 
using the TaqManâ MicroRNA Reverse Transcription Kit (Applied Biosystems). All 
assays were performed in triplicate. For each miRNA, the expression levels, normalized 
to RNU48 (Applied Biosystems), were calculated using 2-∆∆Ct [102]. Pediatric GBM 
samples were subsequently normalized compared to FirstChoice® Human Brain 
Reference Total (Life Technologies®). The expression results in pediatric GBM 
samples were also compared with those from a sample of pediatric non-tumoral cerebral 
cortex processed with the same experimental procedure, whereas the treated cell lines 
were normalized compared to the corresponding untreated cells. 
 
2.2.6. MTT assay 
Cytotoxicity was measured using the MTT assay (in vitro toxicology assay kit MTT 
based, Sigma). The key component of this assay is (3-[4,5-dimethylthiazol-2yl]-2,5-
diphenyl tetrazolium bromide), a yellow salt that mitochondrial dehydrogenases of 
viable cells convert into purple formazan crystals, whose concentration is measured 
spectrophotometrically. We have conducted preliminary experiments to determine the 
best seeding concentration for U87MG, T98G and A172. Consequently, cells were 
seeded at the following densities: A172, 6 × 104 cells/well, U87MG, 4 × 104 cells/well 
and T98G, 2 × 104 cells/well in 24-well plates. After 24 hours, the cells were treated 
with 0.1 and 0.5 μg/ml DOX for 24 and 48 hours. The MTT assay was performed 
following the manufacturer’s instructions. The plates were placed on a shaker for 10 
minutes to enhance solubilization of the precipitate. The absorbance (OD) of each well 
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was then measured on a MULTISKAN FC (Thermo Scientific) microplate reader at a 
test wavelength of 550 nm.  
About co-treatment analysis with Morph, T98G cells were treated with a single dose of 
Morph 20 uM. Two hours after, the excess of Morph was removed and DOX at the 
concentration of 0.5 ug/ml was added for 24h, 48h, 72h and 96h.  
All experiments were performed in triplicate. 
 
2.2.7. TUNEL assay 
Apoptotic cells were detected by the terminal deoxynucleotidyl-transferase-mediated 
dUTP nick end-labeling (TUNEL) assay using in situ cell death detection kit, 
fluorescein (Roche). The best seeding concentration was preliminarily established at the 
following densities: A172, 18 × 104 cells/well, U87MG, 18 × 104 cells/ well, and T98G, 
3 × 104 cells/well in 6-well plates containing cover slips. After 24 hours, the cells were 
treated with 0.1 and 0.5 µg/ml Dox for 30 hours. After treatment, the cover slips were 
washed three times with PBS 1% and fixed in 4% paraformaldehyde solution for 30 
minutes at room temperature. Then, cells were permeabilized by using sodium citrate 
0.1%, TRITON × 100 0,1% for 5 minutes on ice. Finally, the TUNEL assay was 
performed, following the manufacturer’s instructions.  
The results were analyzed by fluorescence microscopy (Leitz, Type 307-148002, 
Wetzlar, Germany), equipped with E4 and N2.1 filters (Leica, Milan, Italy) using an oil 
immersion 100× magnification objective. Images were captured by a Canon digital 
camera using Remote Capture software (provided by Canon, Japan).  
All experiments were performed in triplicate. 
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2.2.8. miR-21 inhibition 
Anti-miR-21 (AMI17000, id No. AM10206) was introduced into T98G cells at a final 
concentration of 10, 30, 60, 90, 120, 160 nM [30]. T98G cells were plated in 24-well 
plates (2 × 104cells/well) and transfected 48 hours later using Lipofectamine® RNAi 
Max Transfection Agent (Invitrogen). The lowest possible concentration that achieved 
the most significant inhibition was chosen as the optimal dosage. Cells were transfected 
with the optimal dosage of 60 nM. To study the concomitant effects of miR-21 
inhibition and DOX, cells were seeded into 6 well-plates at 4 × 104 cells/well and then 
transfected with anti-miR-21 at 60 nM, with or without DOX treatment at 0.5 µg/ml, for 
72 hours [30]. 
 
2.2.9. MTT analysis on T98G cells transfected with anti-miR-21 
T98G cells transfected with anti-miR-21 at 60 nM were subjected to MTT assay. Cells 
were seeded into 24 well-plates at 3 × 104 cells/well, transfected with anti-miR-21 at 60 
nM for 24 hours and then treated with DOX. MTT analysis was performed after 72 
hours of DOX treatment, following the manufacturer’s instructions. The OD of each 
well was measured on a MULTISKAN FC (Thermo Scientific) microplate reader at a 
test wavelength of 550 nm.  
All experiments were performed in triplicate. 
 
2.2.10. TUNEL analysis on T98G cells transfected with anti-miR-21 
T98G cells transfected with anti-miR-21 at 60 nM were subjected to TUNEL assay. 
Cells were seeded into 6 well-plates containing cover slips at 4 × 104 cells/well, 
transfected with anti- miR-21 at 60 nM for 24 hours and then treated with DOX. 
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TUNEL analysis was performed after 72 hours of DOX treatment and the results were 
analyzed by fluorescence microscopy, as described above.  
All experiments were performed in triplicate. 
 
2.2.11. Western blot analysis 
After washing the cells with phosphate buffered saline (PBS), monolayers of GBM cells 
were lysed in ice-cold buffer (NaCl 0.9%, TRIZMA-HCl 20 mmol/L pH 7.6, Triton X-
100 0.1%, phenylmethylsulfonyl fluoride 1 mmol/L, leupeptin 0.01%) and centrifuged 
at 4°C for 10 minutes at 10,000g. The protein content of the supernatants was 
determined by using a bicinchonic acid (BCA) protein assay kit with bovine serum 
albumin (BSA) as standard. The cell lysate was mixed 1:1 with sample buffer 
(TRIZMA-HCl 20 mmol/L pH 6.8, glycerol 20%, sodium dodecyl sulfate (SDS) 2%, β-
mercaptoethanol 5%, and bromophenol blue 0.025%) and boiled. SDS-polyacrylamide 
gel electrophoresis (SDS-PAGE) was performed using 8% acrylamide for the separating 
and stacking gel, respectively. Proteins were transferred to nitrocellulose membrane. 
Blots were blocked with blocker BSA 5% solution in PBS and incubated overnight at 
4°C with the primary antibodies. Blots were further incubated with secondary 
antibodies conjugated with horseradish peroxidase for 2 hours at room temperature and, 
finally, incubated with SuperSignal West Pico Chemiluminescent for 5 minutes and 
exposed to CL-Xposure.  
T98G tumor cells were seeded at the density of 6x105 in Petri dishes to be treated, with 
a single dose of Morph 20 uM. Two hours after, the excess of Morph was removed and 
DOX at the concentration of 0.5 ug/ml was added for 6h, 24h, 48h, 72h and 96h. 
Western blot analysis was performed as previously described. The following primary 
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antibodies were used: anti-P-gp (C219) monoclonal antibody (Gene Tex), anti-BCRP 
monoclonal antibody (Millipore) and anti-β-actin monoclonal antibody (Sigma 
Aldrich). 
 
2.2.12. Statistical analysis 
Statistical analysis of in vitro drug assays was performed by using the one-way 
ANOVA test and post hoc Bonferroni-corrected t-test on the software version Graph 
Pad Prism 5.00.  
A level of p < 0.05 was accepted as statistically significant. 
Statistical analysis of expression studies of pediatric GBMs was performed by using the 
t-test and/or Levene test and the U Mannwhite test on the software package SPSS19. 
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2.3. Results 
 
2.3.1. Pediatric patients characteristics  
Nine pediatric patients were enrolled in the study. Their main clinical characteristics are 
summarized in Table 1. Median age at the time of diagnosis was 8 years old (range: 1-
15 years). All had been treated with chemotherapy and/or radiotherapy according to 
current front-line therapeutic studies of the Associazione Italiana Ematologia Oncologia 
Pediatrica (AIEOP). All underwent to surgery for tumor resection; in 2 of 9 cases a 
radical resection was performed. The median follow-up time was 10 months (range: 3-
24 months). 
 
Table 1. Clinical characteristics of pediatric patients with GBM 
 
ID Gender Age at diagnosis (years) Surgery 
First-line 
treatment 
Best 
response 
FU 
(months) Status 
1 F 12 P-debulk TMZ + RT PR 8 DOD 
2 F 1 C-debulk HDCT CR 14 DOD 
3 M 9 P-debulk VNR + RT PR 12 DOD 
4 F 1 C-debulk HDCT + RT CR 24 DOD 
5 M 4 P-debulk HDCT PR 3 DOD 
6 F 8 P-debulk VNR + RT PR 19 DOD 
7 M 15 P-debulk VNR + RT PR 8 DOD 
8 M 12 Biopsy TMZ + RT PR 7 DOD 
9 F 7 P-debulk TMZ + RT PR 10 DOD 
P-debulk: partial debulking; C-debulk: complete debulking; RT: radiotherapy; TMZ: temozolomide; 
HDCT: high-dose chemotherapy; CR: complete response; PR: partial response; FU: follow-up; DOD: 
dead of disease. 
 
2.3.2. miRNA expression in pediatric glioblastoma 
Analysis of the series of 9 pediatric GBMs showed an overlapping expression pattern 
for all 5 miRNAs investigated, characterized by overexpression of miR-21 and reduced 
or lack of expression of miR-7, miR-124, miR-128 and miR-137. 
The results of miRNA assays were compared to two different reference samples, 
FirstChoice® Human Brain Reference Total and pediatric non-tumoral cerebral cortex. 
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Both analyzes yielded the same results. Differences in expression levels of 4/5 miRNAs 
were observed among the pediatric GBM sample. This is likely due to cell heterogeneity 
in the samples (Figure 2). No expression of miR-128 was detected. 
 
Figure 2. Expression of miR-21, miR- 7, miR-124 e miR-137 in 9 pGBMs, calculated 
as 2-∆∆Ct; REF, FirstChoice® Human Brain Reference Total. 
 
 
 
 
No significant differences in outcome were detected between patients with different 
levels of miR-21 expression.  
 
2.3.3. miRNA expression in U87MG, A172, and T98G cell lines 
In order to evaluate the effect of DOX treatment on miR-21, miR-7, miR-124, miR-128 
and miR-137 expression, we measured basal miRNA levels. 
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We observed low endogenous or no expression of miR-7, miR-124, miR-128 and miR-
137 in A172, U87MG, and T98G untreated cells. In contrast, miR-21 was 
overexpressed in untreated A172, U87MG and T98G cells. 
 
2.3.4. Glioblastoma cell lines and doxorubicin resistance  
Chemosensitivity was evaluated in three GBM cell lines treated for 24 and 48 hours 
with 0.1 and 0.5 µg/ml of DOX (Figure 3). The lowest possible concentrations that 
achieved the most significant results were chosen as the optimal dosage. No statistically 
significant difference was observed after 24 hours of treatment between either U87MG 
or T98G vs control, while A172 exhibited a statistically significant difference at both 
DOX concentrations used (OD values 0.6 ± 0.23 for 0.1 µg/ml DOX, and 0.6 ± 0.3 for 
0.5 µg/ml DOX, respectively) vs control (OD 0.8 ± 0.2) (P < 0.05) (Figure 3A). Figure 
3B illustrates the cytotoxic effect of DOX at 48 hours of treatment and demonstrates 
that A172 and U87MG were sensitive at 0.1 and 0.5 µg/ml concentrations, while T98G 
appeared to be resistant. OD values in A172 were 0.7 ± 0.1 and 0.14 ± 0.06, 
respectively, vs control 1.11 ± 0.1 (P < 0.01); OD values in U87MG were 0.65 ± 0.1 and 
0.3 ± 0.005, respectively, vs control 0.8 ± 0.02 (P < 0.001).  
OD values did not significantly differ between T98G treated and untreated cells. Our 
MTT experiments demonstrated that the most effective cytotoxic DOX dosage was 0.5 
µg/ml. Based on these results, we performed a TUNEL assay to investigate the pro-
apoptotic effects of 0.5 µg/ml of DOX. This dosage induced apoptosis in A172 and 
U87MG but not in T98G, confirming that T98G is a drug resistant cell line (Figure 3C). 
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Figure 3. MTT and TUNEL assay for DOX treatment in A172, T98G, and U87MG cell 
lines. 
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2.3.5. Cytotoxic effect of prolonged exposure to doxorubicin and doxorubicin plus 
morphine in T98G cell line 
The cytotoxic effect of prolonged exposure to DOX or DOX plus Morph treatment was 
evaluated on T98G cells by using MTT assay. About DOX plus Morph treatment, T98G 
cells were treated with a single dose of Morph 20 uM. Two hours after, the excess of 
Morph was removed and DOX at the concentration of 0.5 ug/ml was added for 24h, 
48h, 72h and 96h.  
The data showed that the treatment with Morph does not interfere with the cytotoxic 
effect of DOX that is observed only after prolonged exposure to anthracycline (96h). 
Indeed, there are no statistically significant differences between DOX and DOX plus 
Morph groups, even if a favorable trend for DOX plus Morph was present (Figure 4). 
 
2.3.6. Effects of concomitant doxorubicin treatment and miR-21 inhibition 
To investigate whether miR-21 regulation influences the drug resistant phenotype, we 
transfected anti-miR-21 into the T98G resistant cell line. Different inhibitor 
concentrations (from 10 to 160 nM) were tested. We found that transfection with miR-
21 inhibitor reduced miR-21 expression in a dose dependent manner (Figure 5). The 60 
nM concentration gave the maximal effect and resulted in approximately 80% decrease 
in miR- 21 expression. 
In order to test whether miR- 21 inhibition improves the response of DOX-resistant 
cells to DOX re-challenge, T98G cells were transfected with anti-miR-21 for 24 hours 
and then treated with DOX 0.5 µg/ml.  
TUNEL analysis was performed after 72 hours of DOX treatment. 
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Figure 4. MTT assay for prolonged exposure to DOX or DOX plus Morph in T98G 
cells 
 
The data show that miR-21 inhibition in association with DOX treatment leads to 
increased apoptosis in T98G DOX-resistant cells (Figure 6A).  
In contrast, few apoptotic cells were observed in the corresponding cells treated with 
miR-21 inhibitor or DOX alone (Figure 6B, 6C). 
T98G 72h T98G 96h 
The cytotoxic effect of Morphine (Morf) plus Doxorubicin (Dox) treatment was evaluated on 
T98G cells by using MTT assay. T98G cells were treated with a single dose of Morphine 20 uM. 
Two hours after, the excess of Morphine was removed and Doxorubicin at the concentration of 
0.5 ug/ml was added for 24h, 48h, 72h and 96h. The data showed that the treatment with 
Morphine plus Doxorubicin does not interfere with the cytotoxic effect of chemotherapy that is 
observed  only after prolonged exposure to anthracycline (96h). **p<0.01; ***p<0.001 . 
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Figure 5. Transfection with miR-21 inhibitor in T98G cells 
 
Figure 6D demonstrates that the treatment with miR-21 inhibitor (overall 96 hours) plus 
DOX (for 72 hours) resulted in a significant 23% increase in the apoptotic rate when 
compared with DOX treatment alone (Figure 6D). 
Based on these results, we tested the chemosensitivity of GBM cells treated with miR-
21 inhibitor plus DOX by the MTT assay (Figure 6E). 
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Transfection with miR-21 inhibitor reduces miR-21 expression in T98G cells in a dose dependent 
manner. BC is a blank transfection control used in comparative CT-fold change analysis (A) 
Levels (mean ± SD) of miR-21 expression in the T98G cell line before (T98G-P) and after 
transfection (T98G-T) with miR-21 inhibitor  60 nM were assessed by qRT-PCR. * p<0.05.  
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Figure 6. MTT and TUNEL assay for miR-21 inhibitor plus DOX in T98G cells 
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TUNEL assay, showing apoptotic nuclei in green. A: miR-21 inhibitor plus DOX B: miR-21 
inhibitor alone. C: DOX alone. D: increased apoptotic rate after concomitant treatment with 
miR-21 inhibitor 60 nM and DOX 0.5 !g/ml (**p<0.01). Bar chart shows the percentage (mean 
± SD) of apoptotic cells counted from three randomly selected view fields. 
E: Cytotoxicity response of T98G cells transfected with miR-21 inhibitor 60 nM (96 h) and 
treated with DOX 0.5 ug/ml (72 h). Data are presented as mean±SD (error bar). ***p<0.001 
inhibitor plus DOX vs control. 
The data obtained have validated the possible association of miR-21 with drug resistance of 
T98G cells. Combined DOX and miR-21 inhibitor therapy may regulate anthracyclines 
resistance via augmented apoptotic pathway. 
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The data show that only the concomitant use of miR-21 inhibitor and DOX is effective 
in inhibiting the growth of T98G cells. While treatment with miR-21 inhibitor or DOX 
alone has no effect, the viability of T98G cells was largely reduced when the two 
substances were used in combination. 
 
2.3.7. P-gp and BCRP expression in T98G cells before and after doxorubicin and 
morphine treatment 
P-gp and BCRP expression was evaluated on T98G cells by using western blot analysis, 
before and after treatment with DOX or DOX plus Morph. 
T98G cells were treated with a single dose of Morph 20 uM. Two hours after, the excess 
of Morph was removed and Dox at the concentration of 0.5 ug/ml was added for 6h, 
24h, 48h, 72h and 96h.  
Results shows that T98G cells constitutively express BCRP, but not P-gp. Although the 
results require additional investigations both Morph plus DOX and DOX seem to down-
regulate BRCP expression, regardless of the duration of drug exposure (Figure 7). 
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Figure 7. Western blot analysis of BCRP and P-gp expression in T98G cells before and 
after DOX or DOX plus Morph treatment 
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CHAPTER 3. DISCUSSION AND CONCLUSIONS 
 
 
3.1. Discussion 
 
In order to identify miRNAs that are involved in the pathogenesis and development of 
pediatric GBM, we first used quantitative RT-PCR to analyze the expression of 5 
miRNAs that had previously been found to be dysregulated in adult GBM samples 
[103,104]. miR-21 was overexpressed in all 9 pediatric GBM samples investigated, 
while the expression of miR-7, miR-124, miR-12è8 and miR-137 was either reduced or 
absent. 
Anthracyclines such as DOX are commonly used in the treatment of a wide range of 
tumors, including hematological malignancies, many types of carcinoma and soft tissue 
sarcomas [105]. DOX is a chemotherapeutic agent that intercalates into cellular DNA, 
leading to cell death.  
In vitro and in vivo data on HGG models suggest that DOX can be active for these 
tumors [106-108]. Eramo and co-workers have demonstrated that DOX displays high 
antitumor activity against GBM stem cells when it was administered with prolonger 
exposure, in contrast with low activity of etoposide and temozolomide [109]. 
Despite these data, the clinical trials of DOX in patients with GBM have been 
disappointing. Moreover, systemic use of DOX is often limited by cardiac and liver 
toxicity. Additional formulations or delivery strategies are needed. 
It is know that BBB play an important role in chemotherapy resistance in CNS tumors. 
P-gp and BCRP are efflux pumps of the BBB that play an important role in this 
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mechanism. Moreover, we know that Morph pre-treatment facilitates DOX delivery 
beyond the BBB to the brain in the absence of signs of increased acute systemic toxicity 
in the animal model, and this may be due to pharmacological modulation of the ABC 
transporters on the BBB [56,60]. Despite these data, the role of Morph on cancer cells, 
like modulator drug, and the role of cellular expression of P-gp and BCRP are unclear.  
In order to select DOX resistant cell lines for further analysis, we analyzed the cellular 
response to DOX in three GBM cell lines (A172, U87MG and T98G), identifying a 
different behaviors among them. A cytotoxic effect was observed in A172 and U87MG 
after 48 hours of DOX treatment while T98G cells appeared to be resistant to the drug. 
This was confirmed by the finding of apoptosis induction following DOX treatment in 
A172 and U87MG, but not in T98G. 
On these cells we analyzed the expression of the 5 miRNAs described above; only miR-
21 exhibited a different expression level in all cell lines. Like pediatric GBM samples, 
DOX resistant T98G cells have shown a significant expression of miR-21.  
The selected clone was used to study mechanisms of drug resistance. 
To validate the possible association of miR-21 with drug resistance of T98G cells, we 
investigated the effects of a specific miR-21 inhibition on the cells. The data showed 
that the expression level of miR-21 was significantly lower in T98G transfected cells 
(T98G-T) than in the parental control cells (T98G-P). Moreover, the transfected cell line 
showed a high apoptotic rate compared to the control after DOX treatment. Our results 
suggest that combined DOX and miR-21 inhibitor therapy may regulate DOX resistance 
via augmented apoptotic pathway. 
In order to evaluate the role of Morph in co-treatment with DOX in resistant T98G cells, 
we investigated the cytotoxic effect of the combination treatment, with normal and 
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prolonged exposure. In these cells, Morph did not seem to add a significant cytotoxic 
effect to DOX, although a trend was present. Only the prolonged exposure to DOX had 
induced a significant cytotoxic effect on T98G cells, with or without Morph co-
treatment.  
Therefore, we evaluated the expression of P-gp and BCRP on T98G cells by western 
blot analysis, before, during and after treatment with DOX or DOX plus Morph. 
In our experience, T98G cells constitutively express BCRP, but not P-gp. During and 
after treatment, DOX and DOX plus Morph seem to down-regulate BRCP expression. 
The down-regulation was independent from time of exposure of the drugs. 
 
 
3.2. Conclusions and future developments  
 
Different signal transduction pathways seem to be involved in the chemoresistance 
mechanisms of GBMs. miRNAs are candidate modulators of the response to 
antineoplastic agents of these malignant tumors. 
miR-21 is one of the most investigated miRNAs in human cells, and its expression is 
significantly up-regulated in several tumors. miR-21 expression has been correlated 
with tumor grade and has been proposed as a marker of tumor progression [110,111]. 
miR-21 seems to regulate drug resistance in various cancers.  
High levels of miR-21 are a common feature of adult GBM [112].  
In our study, we have demonstrated that miR-21 are over-expressed even in pediatric 
GBMs. Moreover, we have seen that miR-21 play an important role in cellular 
chemoresistance to DOX in GBM.  
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Regarding the modulation of cellular resistance to DOX by Morph, in our experience 
only the prolonged exposure to DOX may have a role in this mechanism. On this point, 
it has already been demonstrated that DOX displays high antitumor activity against 
GBM stem cells when it was administered with prolonger exposure [109]. 
Moreover, in our study, cellular expression and down-regulation of BCRP seems to be 
not correlated to DOX resistance, and independent to Morph exposure.  
About future perspectives, our study provides evidence that miR-21 inhibition in 
addition to pharmacological treatment could pave the way to new effective approaches 
for reversing drug resistance in GBM.  
In addition, another way for reversing the cellular resistance to DOX in GBM could be 
the prolonged exposure to the drug.  
Further trials “in vivo” are needed to evaluate these theories.  
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